Results of the AIEOP AML 2002/01 multicenter prospective
trial for the treatment of children with acute myeloid
leukemia
by Andrea Pession, Riccardo Masetti, Carmelo Rizzari, Maria Caterina Putti, Fiorina
Casale, Franca Fagioli, Matteo Luciani, Luca Lo Nigro, Giuseppe Menna, Concetta
Micalizzi, Nicola Santoro, Anna Maria Testi, Marco Zecca, Andrea Biondi, Martina
Pigazzi, Sergio Rutella, Roberto Rondelli, Giuseppe Basso, and Franco Locatelli
Blood
Volume 122(2):170-178
July 11, 2013
©2013 by American Society of Hematology
Schematic representation of the induction and consolidation courses employed for treating
patients enrolled in the AIEOP AML 2002/01 trial.
Andrea Pession et al. Blood 2013;122:170-178
©2013 by American Society of Hematology
Flowchart of patients enrolled in the 2000/01 AML protocol.
Andrea Pession et al. Blood 2013;122:170-178
©2013 by American Society of Hematology
Eight-year probability of OS and EFS for the whole cohort of 482 children enrolled in the AIEOP
AML 2002/01 trial.
Andrea Pession et al. Blood 2013;122:170-178
©2013 by American Society of Hematology
Eight-year probability of OS, EFS, DFS, and CI of relapse for SR and HR children enrolled in the
AIEOP AML 2002/01 trial.
Andrea Pession et al. Blood 2013;122:170-178
©2013 by American Society of Hematology